Predictive Preclinical Models for AMD: hVEGFA & hANGPT2 Humanized Mice
For nearly two decades, targeting Vascular Endothelial Growth Factor (VEGF) was the singular gold standard for treating retinal vascular diseases. However, as we settle into 2026, the landscape has fundamentally changed. While anti-VEGF therapies like Aflibercept revolutionized care, the industry is now confronting the ceiling of monotherapy: resistance, frequent injection burdens, and incomplete visual recovery.
The 2024-2025 market success of Faricimab (Vabysmo)—which generated approximately 4.6 billion USD in sales in 2024 alone—has validated a crucial hypothesis: Blocking VEGF is good; stabilizing the vessel via Angiopoietin-2 (Ang-2) is better.
To develop the next challenger to Faricimab or Eylea HD, researchers need preclinical tools that reflect this dual-pathway complexity. Standard wild-type mice are no longer sufficient for testing human-specific bispecific antibodies.
1. Beyond Anti-VEGF: The Rise of Bispecifics and New Preclinical Challenges in AMD
Vascular stability is a balancing act. While VEGFA drives the proliferation of endothelial cells, Angiopoietin-2 (Ang-2) acts as the "destabilizer."
Physiological State: Ang-1 signals via the Tie2 receptor to maintain vessel integrity.
Pathological State: In nAMD or Diabetic Retinopathy (DR), Ang-2 levels rise, antagonizing Tie2. This sensitizes vessels to VEGF, leading to leakage and inflammation.
Recent research reinforces that simultaneous inhibition of VEGFA and Ang-2 not only reduces neovascularization but also normalizes the vessel structure, reducing leakage more effectively than anti-VEGF alone.
Figure 1. Faricimab mechanism of action overview [5].
2. Dual Signaling: Why VEGF & Ang-2 Targets Matter
Developing a bispecific antibody (BsAb) or a combination therapy presents a unique challenge: Species Specificity.
If your candidate drug binds human VEGF and human Ang-2, testing it in a wild-type mouse (with murine proteins) often yields poor cross-reactivity data. Furthermore, the traditional laser-induced Choroidal Neovascularization (CNV) model—while useful—creates an acute injury that doesn't fully capture the spontaneous, chronic nature of human AMD.
To bridge this gap, Cyagen has developed a suite of next-generation ophthalmic models designed for 2026's drug development standards.
3. Preclinical Bottleneck: When Models Don't Match the Real Mechanism
1. The "Spontaneous" Chronic AMD Disease Model: hVEGFA-TG Mice
For researchers studying the chronic progression of AMD without the variability of laser injury, the hVEGFA-TG mouse offers a robust solution. By driving human VEGFA expression specifically in the retina (via the bovine rhodopsin promoter), this model develops spontaneous retinal and choroidal vascular lesions.
Key Advantages:
Natural Progression: Lesions develop naturally, mimicking the pathological overexpression seen in patients.
Proven Sensitivity: Validation data confirms that the model responds to clinical standards like Aflibercept, with significant reduction in vascular leakage.
Intact Structure: The eye structure remains intact, allowing for precise morphological assessment via OCT and fundus imaging.
Figure 2. Pharmacodynamic validation of VEGF-targeted drug.
2. The "Bispecific" Testing Platform: B6-hVEGFA/hANGPT2 Mice
This is the critical tool for the "Faricimab era." The B6-hVEGFA/hANGPT2 mouse features the full genomic replacement of murine Vegfa and Angpt2 with their human counterparts.
4. Why this Matters for your Pipeline: Humanized Target Accuracy in R&D
Target Accuracy: Your human-specific antibody recognizes the physiological targets in the mouse.
Dual Pathway Evaluation: It allows for the precise evaluation of bispecific antibodies or combination therapies that modulate the Ang/Tie and VEGF pathways simultaneously.
Synergy: Can be combined with immune checkpoint humanized models (like PD-1/PD-L1) for immuno-oncology research, as VEGF/Ang-2 also plays a massive role in the tumor microenvironment.
5. Aligning Models with AMD Reality
As the clinical focus shifts toward vascular normalization and multi-target inhibition, your preclinical data must tell a consistent story. Whether you are developing a biobetter for nAMD or a novel bispecific for oncology, relying on surrogate antibodies in wild-type mice is a risk you don't need to take.
By utilizing models like the hVEGFA-TG (for spontaneous pathology) and the Dual hVEGFA/hANGPT2 (for precise drug targeting), you ensure that your efficacy data is not just positive—but predictive.
References
[1] Sha L, Zhao Y, Li S, Wei D, Tao Y, Wang Y. Insights to Ang/Tie signaling pathway: another rosy dawn for treating retinal and choroidal vascular diseases. J Transl Med. 2024 Oct 4;22(1):898.
[2] Leong A, Kim M. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer. Int J Mol Sci. 2020 Nov 18;21(22):8689.
[3] China Medical System Holdings Limited. 2024 Annual Report. Hong Kong: China Medical System Holdings Limited; 2024.
[4] F. Hoffmann-La Roche Ltd. Communications appendix tables_FY 2024 Sales + Results [Internet]. Basel, Switzerland: F. Hoffmann-La Roche Ltd.; 2025.
[5] Ferro Desideri L, Traverso CE, Nicolò M, Munk MR. Faricimab for the Treatment of Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration. Pharmaceutics. 2023 May 5;15(5):1413.
